Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Requirements for Hospitals Offering Mixed Care in Economic Zones
The Central Social Insurance Medical Council (Chuikyo) on November 19 endorsed, after some fine-tuning, eligibility requirements for hospitals that can provide publicly uninsured healthcare services together with insured ones in a fast-track senshin-iryo scheme allowed in Tokyo and Kansai economic…
To read the full story
Related Article
- MHLW Picks 4 Hospitals Eligible for Special Mixed Care Scheme in Tokyo Economic Zone
February 20, 2015
- 5 Experts Likely to Review Regenerative Medicines for Expedited Senshin-Iryo Scheme
November 10, 2014
- Chuikyo OKs New Review Organs for Regenerative Medicines and Medical Devices under Senshin-Iryo System
October 24, 2014
- Mixed Care to Be Boosted in Tokyo, Kansai Special Economic Zones: Panel
March 31, 2014
REGULATORY
- Update: DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
- MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
- MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…